Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria (ACTUGA2)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Most malaria deaths occur within 48 hours of onset of symptoms, and in rural areas with poor access to health facilities, home management of malaria (HMM) can improve the timeliness of treatment and reduce malaria mortality by up to 50%. In order to maximize both coverage and impact, ACTs should be deployed in HMM programmes, as well as in formal health facilities. Up to 80% of malaria cases are treated outside the formal health sector and shops are frequently visited as the first (and in some cases only) source of treatment. Strategies to deploy ACTs in Africa thus also need to examine the role of shops in home management and to ensure that drugs sold are appropriate. The current practice of presumptive treatment of any febrile illness as malaria (both at health facilities and in the context of HMM) based solely on clinical symptoms without routine laboratory confirmation, results in significant over-use of antimalarial drugs. With ACT being a more costly regimen, it is important to be more restrictive in its administration and rapid diagnostic tests (RDTs) provide a simple means of confirming malaria diagnosis in remote locations lacking electricity and qualified health staff.
This study therefore proposes to evaluate the feasibility, acceptability, and cost-effectiveness of using RDTs to improve malaria diagnosis and treatment by community-based drug distributors.The accuracy of RDTs, and the acceptability of this approach, will be evaluated in both low and high transmission areas.
| Condition | Intervention |
|---|---|
|
Fever Malaria |
Device: Rapid diagnostic test Other: presumptive malaria treatment |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria: Comparative Trials in Two Areas of High and Low Transmission in Uganda |
- Proportion of patients given prompt effective treatment by CDDs: % of <5-year-old children diagnosed with malaria who receive appropriate ACT treatment within 24 hours of onset of malaria. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- Coverage of prompt effective treatment: % of <5-year-old children with fever who received ACT treatment within 24 hours of onset of malaria, measured through household surveys. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
| Enrollment: | 2000 |
| Study Start Date: | March 2010 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Rapid diagnostic test and treatment |
Device: Rapid diagnostic test
Use of rapid daignostic tests for diagnosis of malaria
|
| Treatment without rapid daignostic test |
Other: presumptive malaria treatment
Treatment of malariabased on clinical diagnosis without use of diagnostic test
|
Eligibility| Ages Eligible for Study: | 5 Months to 59 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children aged between 6 months and 5 years (< 5 years)reported with fever by the mother/ caretaker of the child
- Children with uncomplicated malaria/ fever episodes
- Children whose mothers consent to participate
Exclusion Criteria:
- Children aged less 6 months or greater than 4 years (≥ 5 years)
- Children requiring referral to a health facility (severe malaria, complicated fever episode, convulsions/fits, loss of consciousness, and other danger signs)
- Children whose mothers refuse to consent
Contacts and Locations| Uganda | |
| Rukungiri District | |
| Rukungiri, Uganda, 0000 | |
| Principal Investigator: | Richard Ndyomugyenyi, MD | Ministry of Health, Uganda |
More Information
Publications:
| Responsible Party: | Pascal Magnussen, senior researcher, DBL -Institute for Health Research and Development |
| ClinicalTrials.gov Identifier: | NCT01048801 History of Changes |
| Other Study ID Numbers: | ACTUGA2 |
| Study First Received: | January 13, 2010 |
| Last Updated: | October 11, 2012 |
| Health Authority: | United Kingdom: National Health Service |
Keywords provided by DBL -Institute for Health Research and Development:
|
History of fever measured fever |
Additional relevant MeSH terms:
|
Fever Malaria Body Temperature Changes |
Signs and Symptoms Protozoan Infections Parasitic Diseases |
ClinicalTrials.gov processed this record on May 21, 2013